Navigation Links
NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
Date:12/5/2013

LOS ANGELES, Dec. 5, 2013 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/898,675 entitled "Systems, Devices and Methods For Treatment of Neurological Disorders and Conditions." The patent application, exclusively licensed to NeuroSigma, is owned by The Regents of the University of California (Regents) as a result of research conducted by physicians and scientists at the University of California, Los Angeles (UCLA). Morgan, Lewis & Bockius LLP has represented the Regents in the prosecution of this patent application and other related applications. Haynes & Boone LLP has represented NeuroSigma.

The method and system claims of the patent application cover the use of trigeminal nerve stimulation (TNS) with cutaneous electrodes for the treatment of neurological disorders, including but not limited to epilepsy, movement disorders, migraine, daily chronic headache, and acute brain injury. 

"We applaud Dr. Christopher DeGiorgio, Dr. Ian Cook and the other inventors for developing this non-invasive neuromodulation technology," said Leon Ekchian, Ph.D., President & CEO of NeuroSigma. "NeuroSigma has the exclusive rights to a large portfolio of pending TNS-related US patent applications and their foreign counterparts. We are delighted to have received our second Notice of Allowance related to this portfolio. Together with the issued patent covering neuropsychiatric applications of eTNS, this will further strengthen our position in the marketplace," added Dr. Ekchian.

The development of TNS for neurological indications has been spearheaded by Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma, and Professor of Neurology at UCLA. "As an inventor, I am very pleased to see that over 10 years of research by our team is reaching fruition, and will now be covered by a US patent," said Dr. DeGiorgio.

Background – The Monarch eTNS System from NeuroSigma

In August 2012, NeuroSigma received CE Mark approval in the European Union for NeuroSigma's first TNS product, the Monarch™ eTNS™ System, for the adjunctive treatment of drug-resistant epilepsy (DRE) and major depressive disorder (MDD) for adults and children 9 years and older. In addition, the Monarch™ eTNS™ System also received a Class II medical device license from Health Canada in April of 2013 covering the use of the system for treatment of DRE and MDD for adults and children 9 years and older.  NeuroSigma is currently marketing the Monarch™ eTNS™ System to patients in the European Union and Canada with a physician's prescription.

The Monarch™ eTNS™ System is composed of a cell-phone sized pulse generator that delivers electrical signals to the trigeminal nerve, which are transmitted through lead wires to a single-use patch that is applied to the forehead, thereby non-invasively modulating activity in targeted brain regions. Patients may conveniently self-administer the Monarch™ eTNS™ System at home and typically use the device while sleeping.

Background - TNS

The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain, bilaterally and at high frequency. The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD, ADHD and other disorders. 

Trigeminal Nerve Stimulation (TNS) is the electrical stimulation of branches of the trigeminal nerve, which are located near the surface of the forehead.  Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions.

CAUTION: In the United States, eTNS™ is an investigationaldevice and is limited by Federal (or United States) law to investigational use.  The U.S. Food and Drug Administration has given NeuroSigma conditional approval to proceed with a pivotal Phase 3 clinical trial of eTNS in drug resistant epilepsy. Completion of that Phase 3 study is necessary before the FDA will consider permitting the marketing and sale of eTNS in the United States.

eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc.

About NeuroSigma, Inc.  

NeuroSigma is a Los Angeles-based life sciences company focused on developing trigeminal nerve stimulation (TNS) based products with the potential to transform the lives of patients suffering from major neurological and neuropsychiatric disorders, including epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD). Please visit http://www.neurosigma.com for more corporate information and http://www.monarch-etns.com for more information on the Monarch eTNS System.

Forward-Looking Safe Harbor Statement: 
This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding our eTNS™ system.  These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.


'/>"/>
SOURCE NeuroSigma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Announces FDA Approval to Commence Phase III Trial
2. NeuroSigma Announces Debut of Its Monarch eTNS System in Canada
3. NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
4. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
5. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
6. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
7. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
8. NeuroSigma Receives CE Certification
9. NeuroSigma Receives Global Quality Control Certification
10. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
11. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):